title: Outcomes of Trabeculectomy With Mitomycin-C in Uveitis Associated With Vogt-Koyanagi-Harada Disease.
abstract: To evaluate the outcomes of trabeculectomy with mitomycin-C (MMC) in uveitis associated with Vogt-Koyanagi-Harada disease (VKH).
  
  
  
  Retrospective cohort study included 27 eyes of 15 patients with uveitic glaucoma associated with VKH disease who underwent trabeculectomy with MMC as a first glaucoma procedure at King Khaled Eye Specialist Hospital, Riyadh, Saudi Arabia between 1992 and 2011. The main outcome measures were: the intraocular pressure (IOP), the number of antiglaucoma medications, the presence of visually threatening complications, and the need for further surgeries to control the IOP.
  
  
  
  The mean follow-up was 78.19 months. The IOP decreased significantly from a mean of 40.15±7.0 to 13.12±6.9 mm Hg on the last follow-up (P<0.01) as well as during the whole follow-up period. The number of medications needed to control the IOP also decreased significantly from 3.89±0.6 to 1.04±1.3. The cumulative probabilities of success were 77.8%, 74.1%, 63.0%, and 51.9% at 12, 24, 36, and 48 months postoperatively, respectively. The most common complications were cataract development and progression (53.8%), hypotony (IOP≤5 mm Hg) (33.3%), choroidal effusion (7.4%), and decompressive retinopathy (7.4%). Eight eyes (29.6%) needed a second procedure to control the IOP.
  
  
  
  Trabeculectomy with MMC offers an acceptable intermediate term success and IOP control in uveitic glaucoma associated with VKH. However, significant number of eyes needed further procedures to control the pressure. Therefore, continuous monitoring of the pressure is important.
authors.affiliation: *Department of Ophthalmology, College of Medicine, King Saud University †Glaucoma Division, King Khaled Eye Specialist Hospital, Riyadh ‡King Abdullah Medical City, Makkah, Saudi Arabia.
authors.forename: Faisal A
authors.initials: FA
authors.lastname: Almobarak
authors.forename: Ali H
authors.initials: AH
authors.lastname: Alharbi
authors.forename: Jose
authors.initials: J
authors.lastname: Morales
authors.forename: Ibrahim
authors.initials: I
authors.lastname: Aljadaan
mesh_terms: D000328:Adult; D000477:Alkylating Agents / Q000008:administration & dosage*; D015331:Cohort Studies; D003131:Combined Modality Therapy; D003228:Conjunctiva / Q000187:drug effects*; D005260:Female; D005901:Glaucoma / Q000503:physiopathology / Q000601:surgery*; D006801:Humans; D007429:Intraocular Pressure / Q000502:physiology; D008297:Male; D016685:Mitomycin / Q000008:administration & dosage*; D011183:Postoperative Complications; D012189:Retrospective Studies; D014065:Tonometry, Ocular; D014130:Trabeculectomy / Q000379:methods*; D016896:Treatment Outcome; D014605:Uveitis / Q000503:physiopathology / Q000601:surgery*; D014607:Uveomeningoencephalitic Syndrome / Q000503:physiopathology / Q000601:surgery*; D055815:Young Adult
chemical_list: D000477:Alkylating Agents; D016685:Mitomycin